| 000 | 01898 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515133913.0 | ||
| 264 | 0 | _c20081224 | |
| 008 | 200812s 0 0 eng d | ||
| 022 | _a0306-0225 | ||
| 024 | 7 |
_a10.1007/978-1-4020-8831-5_19 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBillich, Andreas | |
| 245 | 0 | 0 |
_aSphingolipid metabolizing enzymes as novel therapeutic targets. _h[electronic resource] |
| 260 |
_bSub-cellular biochemistry _c2008 |
||
| 300 |
_a487-522 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAldehyde-Lyases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aAnaphylaxis _xphysiopathology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aAtherosclerosis _xphysiopathology |
| 650 | 0 | 4 |
_aBacterial Infections _xphysiopathology |
| 650 | 0 | 4 |
_aCeramides _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCyclooxygenase 2 _xmetabolism |
| 650 | 0 | 4 |
_aDendritic Cells _xphysiology |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xpharmacology |
| 650 | 0 | 4 |
_aLeukocytes _xphysiology |
| 650 | 0 | 4 |
_aLysophospholipids _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aMacrophages _xphysiology |
| 650 | 0 | 4 |
_aMast Cells _xphysiology |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
| 650 | 0 | 4 |
_aPhosphotransferases (Alcohol Group Acceptor) _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aRNA, Small Interfering _xtherapeutic use |
| 650 | 0 | 4 |
_aSphingolipids _xmetabolism |
| 650 | 0 | 4 |
_aSphingomyelin Phosphodiesterase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSphingosine _xanalogs & derivatives |
| 700 | 1 | _aBaumruker, Thomas | |
| 773 | 0 |
_tSub-cellular biochemistry _gvol. 49 _gp. 487-522 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/978-1-4020-8831-5_19 _zAvailable from publisher's website |
| 999 |
_c18222907 _d18222907 |
||